Content area

Abstract

Over the last decade, genetic characterization of T-cell acute lymphoblastic leukemia (T-ALL) has led to the identification of a variety of chromosomal abnormalities. In this study, we used array-comparative genome hybridization (array-CGH) and identified a novel recurrent 9q34 amplification in 33% (12/36) of pediatric T-ALL samples, which is therefore one of the most frequent cytogenetic abnormalities observed in T-ALL thus far. The exact size of the amplified region differed among patients, but the critical region encloses ∼4 Mb and includes NOTCH1. The 9q34 amplification may lead to elevated expression of various genes, and MRLP41, SSNA1 and PHPT1 were found significantly expressed at higher levels. Fluorescence in situ hybridization (FISH) analysis revealed that this 9q34 amplification was in fact a 9q34 duplication on one chromosome and could be identified in 17–39 percent of leukemic cells at diagnosis. Although this leukemic subclone did not predict for poor outcome, leukemic cells carrying this duplication were still present at relapse, indicating that these cells survived chemotherapeutic treatment. Episomal NUP214-ABL1 amplification and activating mutations in NOTCH1, two other recently identified 9q34 abnormalities in T-ALL, were also detected in our patient cohort. We showed that both of these genetic abnormalities occur independently from this newly identified 9q34 duplication.

Details

Title
A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia
Author
van Vlierberghe P 1 ; Meijerink J P P 1 ; Lee, C 2 ; Ferrando, A A 3 ; Look, A T 3 ; van Wering E R 4 ; Beverloo, H B 5 ; Aster, J C 6 ; Pieters, R 1 

 Erasmus MC/Sophia Children's Hospital, Department of Pediatric Oncology/Hematology, Rotterdam, The Netherlands (GRID:grid.416135.4) 
 Brigham and Women's Hospital, Harvard Medical School, Department of Pathology, Boston, USA (GRID:grid.416135.4) 
 Dana-Farber Cancer Institute, Children's Hospital, Harvard Medical School, Department of Pediatric Oncology, and Division of Hematology/Oncology, Boston, USA (GRID:grid.416135.4) 
 Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands (GRID:grid.476268.9) (ISNI:0000 0004 0395 3851) 
 Erasmus MC, Department of Clinical Genetics, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X) 
 Brigham and Women's Hospital, Harvard Medical School, Department of Pathology, Boston, USA (GRID:grid.5645.2) 
Pages
1245-1253
Publication year
2006
Publication date
Jul 2006
Publisher
Nature Publishing Group
ISSN
08876924
e-ISSN
14765551
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2645705836
Copyright
© Nature Publishing Group 2006.